WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, August 12, 2004

Hide?	Set Name	Query	Hit Count
	DB=USPT; PLUR=YES; OP=ADJ		
☐	L36	5789230.pn. and papilloma virus	1
☐	L35	5789230.pn. and papillomavirus	0
☐	L34	5789230.pn.	1
☐	L33	5855891.pn.	1
	DB=PGPB; PLUR=YES; OP=ADJ		
☐	L32	deleted "L1" epitope	0
☐	L31	deleted "L1" antigne	0
☐	L30	deleted "L1" antignes	0
☐	L29	modified "L1" protein	2
☐	L28	empty virus like particles	4
☐	L27	papillomavirus and empty virus like particles	0
☐	L26	empty virus like particles and papillomavirus	0
☐	L25	L2 and papillomavirus	0
	DB=EPAB; PLUR=YES; OP=ADJ		
☐	L24	WO-9746693-A1.did.	1
☐	L23	WO-9746693-A1.did.	1
	DB=USOC; PLUR=YES; OP=ADJ		
☐	L22	major capsid protein and human papilloma virus modified and nonimmunogenic	0
	DB=EPAB; PLUR=YES; OP=ADJ		
☐	L21	major capsid protein and human papilloma virus modified and nonimmunogenic	0
	DB=JPAB; PLUR=YES; OP=ADJ		
☐	L20	major capsid protein and human papilloma virus modified and nonimmunogenic	0
	DB=DWPI; PLUR=YES; OP=ADJ		
☐	L19	major capsid protein and human papilloma virus modified and nonimmunogenic	1
☐	L18	major capsid protein of human papilloma virus modified to be nonimmunogenic	0
	DB=EPAB; PLUR=YES; OP=ADJ		
☐	L17	ZA-200200886-A.did.	0

☐	L16	EP-1222200-A1.did.	0
	DB=DWPI; PLUR=YES; OP=ADJ		
☐	L15	Antonsson p.in.	4
	DB=EPAB; PLUR=YES; OP=ADJ		
☐	L14	WO-9746693-A1.did.	1
☐	L13	WO-9746693-A1.did.	1
	DB=DWPI; PLUR=YES; OP=ADJ		
☐	L12	Bloch M A.in.	2
☐	L11	Bloch.in. virus like	0
☐	L10	Bloch.in. gene therapy	0
☐	L9	Bloch.in. VLP	0
☐	L8	Bloch.in.	496
☐	L7	Bloch.in. and papillomavirus	0
	DB=USPT; PLUR=YES; OP=ADJ		
☐	L6	Bloch.in. and papillomavirus	1
☐	L5	Bloch.in. and papilomavirus	0
☐	L4	L2 and papillomavirus	1
☐	L3	L2 and papillomairus	0
☐	L2	empty virus like particles	8
☐	L1	papillomavirus and virus like particles	137

END OF SEARCH HISTORY

Items 1-20 of 131

Page 1 of 7 Next

☐ **1:** Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA. Related Articles, Links

Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.
J Virol. 2003 Nov;77(21):11625-32.
PMID: 14557648 [PubMed - indexed for MEDLINE]

☐ **2:** Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, McClements WL, Ludmerer SW, Jansen KU. Related Articles, Links

Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Virology. 2001 Dec 20;291(2):324-34.
PMID: 11878901 [PubMed - indexed for MEDLINE]

☐ **3:** White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, Suzich JA. Related Articles, Links

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.
J Virol. 1999 Jun;73(6):4882-9.
PMID: 10233949 [PubMed - indexed for MEDLINE]

☐ **4:** Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P. Related Articles, Links

Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
J Virol. 2002 Jul;76(13):6480-6.
PMID: 12050360 [PubMed - indexed for MEDLINE]

☐ **5:** Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, Rybicki EP. Related Articles, Links

Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
J Virol. 2003 Aug;77(15):8386-93.
PMID: 12857908 [PubMed - indexed for MEDLINE]

☐ **6:** Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. Related Articles, Links

Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
Virology. 1996 Sep 1;223(1):174-84.
PMID: 8806551 [PubMed - indexed for MEDLINE]

☐ 7: Wang XM, Cook JC, Lee JC, Jansen KU, Christensen ND, Ludmerer SW, McClements WL. Related Articles, Links

Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes.
J Gen Virol. 2003 Jun;84(Pt 6):1493-7.
PMID: 12771418 [PubMed - indexed for MEDLINE]

☐ 8: McClements WL, Wang XM, Ling JC, Skulsky DM, Christensen ND, Jansen KU, Ludmerer SW. Related Articles, Links

A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1.
Virology. 2001 Oct 25;289(2):262-8.
PMID: 11689049 [PubMed - indexed for MEDLINE]

☐ 9: Sadeyen JR, Tourne S, Shkreli M, Sizaret PY, Coursaget P. Related Articles, Links

Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope.
Virology. 2003 Apr 25;309(1):32-40.
PMID: 12726724 [PubMed - indexed for MEDLINE]

☐ 10: Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Related Articles, Links

Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
Virology. 1996 Oct 15;224(2):477-86.
PMID: 8874508 [PubMed - indexed for MEDLINE]

☐ 11: Volpers C, Sapp M, Snijders PJ, Walboomers JM, Streeck RE. Related Articles, Links

Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2.
J Gen Virol. 1995 Nov;76 (Pt 11):2661-7.
PMID: 7595373 [PubMed - indexed for MEDLINE]

☐ 12: Wang X, Wang Z, Christensen ND, Dillner J. Related Articles, Links

Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11.
Virology. 2003 Jun 20;311(1):213-21.
PMID: 12832218 [PubMed - indexed for MEDLINE]

☐ 13: Kawana K, Matsumoto K, Yoshikawa H, Taketani Y, Kawana T, Yoshiike K, Kanda T. Related Articles, Links

A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.
Virology. 1998 Jun 5;245(2):353-9.
PMID: 9636375 [PubMed - indexed for MEDLINE]

☐ 14: Touze A, El Mehdaoui S, Sizaret PY, Mougin C, Munoz N, Coursaget P. Related Articles, Links

The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
J Clin Microbiol. 1998 Jul;36(7):2046-51.

PMID: 9650960 [PubMed - indexed for MEDLINE]

☐ 15: Cason J, Patel D, Naylor J, Lunney D, Shepherd PS, Best JM, McCance DJ. Related Articles, Links

Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes.
J Gen Virol. 1989 Nov;70 (Pt 11):2973-87.
PMID: 2479716 [PubMed - indexed for MEDLINE]

☐ 16: Chen Y, Ghim SJ, Jenson AB, Schlegel R. Related Articles, Links

Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes.
J Gen Virol. 1998 Sep;79 (Pt 9):2137-46.
PMID: 9747722 [PubMed - indexed for MEDLINE]

☐ 17: Christensen ND, Kirnbauer R, Schiller JT, Ghim SJ, Schlegel R, Jenson AB, Kreider JW. Related Articles, Links

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.
Virology. 1994 Nov 15;205(1):329-35.
PMID: 7526536 [PubMed - indexed for MEDLINE]

☐ 18: Kulski JK, Sadleir JW, Kelsall SR, Cicchini MS, Shellam G, Peng SW, Qi YM, Galloway DA, Zhou J, Frazer IH. Related Articles, Links

Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.
Virology. 1998 Apr 10;243(2):275-82.
PMID: 9568027 [PubMed - indexed for MEDLINE]

☐ 19: Ludmerer SW, Benincasa D, Mark GE 3rd, Christensen ND. Related Articles, Links

A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope.
J Virol. 1997 May;71(5):3834-9.
PMID: 9094659 [PubMed - indexed for MEDLINE]

☐ 20: Roden RB, Armstrong A, Haderer P, Christensen ND, Hubbert NL, Lowy DR, Schiller JT, Kirnbauer R. Related Articles, Links

Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.
J Virol. 1997 Aug;71(8):6247-52.
PMID: 9223527 [PubMed - indexed for MEDLINE]

Items 1-20 of 131 Page 1 of 7 Next

Display Summary Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

```
=> d his

     (FILE 'HOME' ENTERED AT 13:03:11 ON 12 AUG 2004)

     FILE 'MEDLINE' ENTERED AT 13:03:19 ON 12 AUG 2004
L1         14951 S PAPILLOMAVIRUS
L2           159 S VLP AND L1
L3          2173 S VIRUS LIKE PARTICLES
L4           321 S L3 AND L1
L5            53 S CARRIER AND L3
L6            46 S EMPTY AND L3
L7            26 S GENE THERAPY AND L3
```

L7 ANSWER 1 OF 26 MEDLINE on STN
AN 2004135757 MEDLINE
DN PubMed ID: 14973544
TI DNA vaccine-encapsulated **virus-like particles** derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration.
AU Takamura S; Niikura M; Li T-C; Takeda N; Kusagawa S; Takebe Y; Miyamura T; Yasutomi Y
CS Department of Bioregulation, Mie University School of Medicine, Tsu, Mie, Japan.
SO Gene therapy, (2004 Apr) 11 (7) 628-35.
Journal code: 9421525. ISSN: 0969-7128.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200407
ED Entered STN: 20040319
Last Updated on STN: 20040722
Entered Medline: 20040721
AB Delivery of foreign genes to the digestive tract mucosa by oral administration of nonreplicating gene transfer vectors would be a very useful method for vaccination and **gene therapy**.
However, there have been few reports on suitable vectors. In the present study, we found that plasmid DNA can be packaged in vitro into a virus-like particle (VLP) composed of open reading frame 2 of hepatitis E virus, which is an orally transmissible virus, and that these VLPs can deliver this foreign DNA to the intestinal mucosa in vivo. The delivery of plasmid DNA to the mucosa of the small intestine was confirmed by the results of immunohistochemical analyses using an expression plasmid encoding human immunodeficiency virus env (HIV env) gp120. After oral administration of VLPs loaded with HIV env cDNA, significant levels of specific IgG and IgA to HIV env in fecal extracts and sera were found. Moreover, mice used in this study exhibited cytotoxic T-lymphocyte responses specific to HIV env in the spleen, Payer's patches and mesenteric lymph nodes. These findings suggest that VLPs derived from orally transmissible viruses can be used as vectors for delivery of genes to mucosal tissue by oral administration for the purpose of DNA vaccination and **gene therapy**.
CT Check Tags: Female; Support, Non-U.S. Gov't
*AIDS Vaccines: GE, genetics
Administration, Oral
Animals
Cell Line
***Gene Therapy**: **MT**, **methods**
*Genetic Vectors: AD, administration & dosage
*Hepatitis E virus: GE, genetics
Immunity, Mucosal
*Intestinal Mucosa: IM, immunology
Mice
Mice, Inbred BALB C
*Open Reading Frames
T-Lymphocytes, Cytotoxic: IM, immunology
CN 0 (AIDS Vaccines); 0 (Genetic Vectors)

L7 ANSWER 2 OF 26 MEDLINE on STN
AN 2003592752 MEDLINE
DN PubMed ID: 14645925
TI Murine pneumotropic virus VP1 **virus-like particles** (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine

polyomavirus VP1 VLPs.

AU Tegerstedt K; Andreasson K; Vlastos A; Hedlund K O; Dalianis T; Ramqvist T
CS Department of Oncology-Pathology, Karolinska Institute, Cancer Center Karolinska R8 : 01, Karolinska Hospital, SE-171 76 Stockholm, Sweden.

SO Journal of general virology, (2003 Dec) 84 (Pt 12) 3443-52.
Journal code: 0077340. ISSN: 0022-1317.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200401
ED Entered STN: 20031217
Last Updated on STN: 20040121
Entered Medline: 20040120

AB The ability of murine pneumotropic virus (MPtV) major capsid protein VP1 to form **virus-like particles** (VLPs) was examined. MPtV-VLPs obtained were used to estimate the potential of MPtV to attach to different cells and to assess some characteristics of the MPtV cell receptor. Furthermore, to evaluate if MPtV-VLPs could potentially complement murine polyomavirus (MPyV) VP1 VLPs (MPyV-VLPs) as vectors for prime-boost **gene therapy**, the capability of MPtV-VLPs to serologically cross react with MPyV-VLPs and to transduce DNA into cells was examined. MPtV VP1 obtained in a recombinant baculovirus system formed MPtV-VLPs readily. MPtV-VLPs were shown by FACS analysis to bind to different cells, independent of MHC class I antigen expression. In addition, MPtV-VLPs did not cause haemagglutination of red blood cells and MPtV-VLP binding to cells was neuraminidase resistant but mostly trypsin and papain sensitive, indicating that the MPtV receptor lacks sialic acid components. When tested by ELISA and in vivo neutralization assays, MPtV-VLPs did not serologically cross react with MPyV-VLPs, suggesting that MPtV-VLPs and MPyV-VLPs could potentially be interchanged as carriers of DNA in repeated **gene therapy** . Finally, MPtV-VLPs were shown to transduce foreign DNA in vitro and in vivo. In conclusion, the data suggest that MPtV-VLPs, and possibly also MPtV, bind to several different cell types, that binding is neuraminidase resistant and that MPtV-VLPs should potentially be able to complement MPyV-VLPs for prime-boost gene transfer in vivo.

CT Check Tags: Human; Support, Non-U.S. Gov't
Animals
*Antibodies, Viral: IM, immunology
Capsid Proteins: IM, immunology
*Capsid Proteins: ME, metabolism
Cell Line
Cercopithecus aethiops
Cross Reactions
DNA-Binding Proteins: ME, metabolism
Enzyme-Linked Immunosorbent Assay
Guinea Pigs
Hemagglutination
Histocompatibility Antigens Class I: ME, metabolism
Mice
N-Acetylneuraminic Acid
Neuraminidase: PD, pharmacology
Neutralization Tests
Papain: PD, pharmacology
Plasmids
Polyomavirus: IM, immunology
*Polyomavirus: ME, metabolism
Polyomavirus: UL, ultrastructure
Protein Binding
Receptors, Virus: CH, chemistry
Receptors, Virus: DE, drug effects

Receptors, Virus: ME, metabolism
Trypsin: PD, pharmacology
RN 131-48-6 (N-Acetylneuraminic Acid)
CN 0 (Antibodies, Viral); 0 (Capsid Proteins); 0 (DNA-Binding Proteins); 0 (Histocompatibility Antigens Class I); 0 (Plasmids); 0 (Receptors, Virus); 0 (polyomavirus capsid protein VP1); EC 3.2.1.18 (Neuraminidase); EC 3.4.21.4 (Trypsin); EC 3.4.22.2 (Papain)

L7 ANSWER 3 OF 26 MEDLINE on STN
AN 2003524218 MEDLINE
DN PubMed ID: 14601522
TI The use of **virus-like particles** for gene transfer.
AU Petry Harald; Goldmann Claudia; Ast Oliver; Luke Wolfgang
CS Berlex Biosciences, 2600 Hilltop Drive, PO Box 4099, Richmond, CA 94804-0099, USA.
SO Current opinion in molecular therapeutics, (2003 Oct) 5 (5) 524-8. Ref: 53
Journal code: 100891485. ISSN: 1464-8431.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200403
ED Entered STN: 20031107
Last Updated on STN: 20040331
Entered Medline: 20040330
AB A major challenge in the field of **gene therapy** is the development of new carrier/delivery systems that lack the disadvantages of current transfer systems. In the past, some time has been spent developing such modified or alternative vectors. A new candidate is represented by **virus-like particles** (VLPs).
It has been shown that recombinant expression of the major structural proteins of many viruses leads to the formation of VLPs. Such VLPs exhibit morphology similar to the empty capsids of the virus from which they are derived. VLPs are non-infectious, have a similar tropism to the natural virus, and show comparable cellular uptake and intracellular trafficking. Since its discovery, VLP technology has gained importance in biomedical research. Although most investigations into VLP technology have dealt with vaccine development, some research groups have demonstrated that VLPs could also represent a useful **gene therapy** delivery system. This review will focus on studies performed with VLPs from members of the Papillomaviridae and Polyomaviridae families.
CT Check Tags: Human
Animals
DNA, Viral: ME, metabolism
***Gene Therapy**
*Gene Transfer Techniques
Genetic Vectors: GE, genetics
Genetic Vectors: IM, immunology

AN 2003510481 MEDLINE
DN PubMed ID: 14557648
TI Identification of a human papillomavirus type 16-**specific epitope** on the C-terminal arm of the major capsid protein **L1**.
AU Carter Joseph J; Wipf Greg C; Benki Sarah F; Christensen Neil D; Galloway Denise A
CS Program in Cancer Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.. jcarter@fhcrc.org
SO Journal of virology, (2003 Nov) 77 (21) 11625-32.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200312
ED Entered STN: 20031101
Last Updated on STN: 20031219
Entered Medline: 20031202

=> d l14 ab

L14 ANSWER 1 OF 1 MEDLINE on STN
AB To characterize epitopes on human papillomavirus (HPV) virus-like particles (VLPs), a panel of mutated **HPV-16** VLPs was created. Each mutated VLP had residues substituted from HPV-31 or HPV-52 **L1** sequences to the **HPV-16 L1** backbone. Mutations were created on the HPV-31 and -52 **L1** proteins to determine if **HPV-16** type-specific recognition could be transferred. Correct folding of the mutated proteins was verified by resistance to trypsin digestion and by binding to one or more conformation-dependent monoclonal antibodies. Several of the antibodies tested were found to bind to regions already identified as being important for HPV VLP recognition (loops DE, EF, FG, and HI). Sequences at both ends of the long FG loop (amino acids 260 to 290) were required for both H16.V5 and H16.E70 reactivity. A new antibody-binding site was discovered on the C-terminal arm of **L1** between positions 427 and 445. Recognition of these residues by the H16.U4 antibody suggests that this region is surface exposed and supports a recently proposed molecular model of HPV VLPs.

=> d l22 2 all

L22 ANSWER 2 OF 3 MEDLINE on STN
AN 97437475 MEDLINE
DN PubMed ID: 9292008
TI A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera.
AU Wang Z; Christensen N; Schiller J T; Dillner J
CS Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden.
SO Journal of general virology, (1997 Sep) 78 (Pt 9) 2209-15.
Journal code: 0077340. ISSN: 0022-1317.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199710
ED Entered STN: 19971013
Last Updated on STN: 19971013
Entered Medline: 19971001
AB A type-specific and neutralizing mouse MAb (V5) against human papillomavirus (HPV) type 16 capsids was found to block the serological reactivity of human sera with the corresponding capsids. Out of 352 human serum samples tested for the presence of IgG against HPV-16, more than 75% of reactive sera were completely blocked by the **V5 antibody**. Type-specific MAbs against HPV-6, -18 and -33 were also found to block serological reactivity with capsids of the corresponding HPV types for the majority of reactive human sera. The results suggest that most antibodies in human sera that are reactive with intact HPV capsids recognize the same or closely related major antigenic determinant(s).
CT Check Tags: Female; Human; Support, Non-U.S. Gov't
Adolescent
Adult
Animals
*Antibodies, Monoclonal
*Antibodies, Viral
Antibodies, Viral: BL, blood
Binding, Competitive
*Capsid: IM, immunology

d 123 1 5 all

L23 ANSWER 1 OF 7 MEDLINE on STN
AN 2004170965 MEDLINE
DN PubMed ID: 15063127
TI **HPV-16 L1** genes with inactivated negative RNA elements induce potent immune responses.
AU Rollman Erik; Arnheim Lisen; Collier Brian; Oberg Daniel; Hall Hakan; Klingstrom Jonas; Dillner Joakim; Pastrana Diana V; Buck Chris B; Hinkula Jorma; Wahren Britta; Schwartz Stefan
CS Department of Virology, Swedish Institute for Infectious Disease Control, Solna, Sweden.. erik.rollman@smi.ki.se
SO Virology, (2004 Apr 25) 322 (1) 182-9.
Journal code: 0110674. ISSN: 0042-6822.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200406
ED Entered STN: 20040406
Last Updated on STN: 20040602
Entered Medline: 20040601
AB Introduction of point mutations in the 5' end of the human papillomavirus type 16 (**HPV-16**) **L1** gene specifically inactivates negative regulatory RNA processing elements. DNA vaccination of C57Bl/6 mice with the **mutated L1** gene resulted in improved immunogenicity for both neutralizing antibodies as well as for broad cellular immune responses. Previous reports on the activation of **L1** by codon optimization may be explained by inactivation of the regulatory RNA elements. The modified **HPV-16 L1** DNA that induced anti-**HPV-16** immunity may be seen as a complementary approach to protein subunit immunization against papillomavirus.
CT Check Tags: Support, Non-U.S. Gov't
Animals
Antibodies, Viral: BL, blood
Antibodies, Viral: IM, immunology
CD4-Positive T-Lymphocytes: IM, immunology
CD8-Positive T-Lymphocytes: IM, immunology
Cells, Cultured
Disease Models, Animal
Genes, Regulator
Genes, Viral
Lymphocyte Activation
Mice
Mice, Inbred C57BL
Neutralization Tests
Oncogene Proteins, Viral: GE, genetics
*Oncogene Proteins, Viral: IM, immunology
Papillomavirus Infections: BL, blood
*Papillomavirus Infections: IM, immunology
Papillomavirus Infections: PC, prevention & control
Papillomavirus, Human: GE, genetics
*Papillomavirus, Human: IM, immunology
Point Mutation
Spleen: IM, immunology
*Vaccination
Vaccines, DNA: AD, administration & dosage
CN 0 (Antibodies, Viral); 0 (Oncogene Proteins, Viral); 0 (Vaccines, DNA); 0 (oncogene viral capsid protein, **L1** human papillomavirus type 16)

L23 ANSWER 5 OF 7 MEDLINE on STN

AN 2003149974 MEDLINE
DN PubMed ID: 12665934
TI Construction and identification of the replication-deficient recombinant vaccinia virus co-expressing **HPV type 16** **L1** and L2 proteins.
AU Han Liqun; Ren Jiao; Liang Yu; Tian Houwen; Zhi Huijun; Luo Weifeng; Lu Zhenhua; Wei Lanlan; Ruan Li
CS Institute of Virology, Chinese Academy of Preventive Medicine, Beijing 100052, China.
SO Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, (2002 Sep) 16 (3) 256-60.
Journal code: 9602873. ISSN: 1003-9279.
CY China
DT Journal; Article; (JOURNAL ARTICLE)
LA Chinese
FS Priority Journals
EM 200311
ED Entered STN: 20030401
Last Updated on STN: 20031113
Entered Medline: 20031112
AB OBJECTIVE: To generate an HPV16 prophylactic vaccine candidate for cervical cancer. METHODS: HPV16 major capsid protein **L1** gene and minor capsid protein L2 gene were amplified using PCR.These genes were **mutated** by PCR site-directed mutagenesis for removal of sequence motifs (TTTTTNT) which would cause transcription termination when expressed from a vaccinia virus early promoter, then inserted into a vaccinia virus expression vector. A strain replication-deficient recombinant vaccinia virus containing the mutant sequences was obtained through a homologous recombination and identified. RESULTS: The nucleotide sequence remained the correct amino acid sequence of the **L1** and L2 proteins after **mutated**. Full-length **L1** and L2 proteins were generated in cells infected with the recombinant virus. The virus strain propagated at very low titer or could not reproduce in some kinds of cell derived from different human tissues. CONCLUSIONS: The authors have generated a strain replication-deficient recombinant vaccinia virus expressing HPV16 **L1** plus L2 proteins as an HPV16 prophylactic vaccine candidate for cervical cancer.
CT Check Tags: Female; Human; Support, Non-U.S. Gov't
Capsid
*Capsid Proteins: GE, genetics
Cell Line
Cervix Neoplasms: VI, virology
Cloning, Molecular
English Abstract
Gene Expression
Genetic Vectors

L25 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:581030 CAPLUS
DN 115:181030
TI Type-specific and cross-reactive epitopes in human papillomavirus type 16 capsid proteins
AU Beiss, Barbara K.; Heimer, Edgar; Felix, Arthur; Burk, Robert D.; Ritter, Diane B.; Mallon, Robert G.; Kadish, Anna S.
CS Dep. Pathol., Albert Einstein Coll. Med., Bronx, NY, 10461, USA
SO Virology (1991), 184(1), 460-4
CODEN: VIRLAX; ISSN: 0042-6822
DT Journal
LA English

=> d l25 2 ab

L25 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AB Rabbit polyclonal and mouse monoclonal antisera were raised to C terminal peptides from the genital human papillomavirus (**HPV**) **16** **L1** and L2 open reading frames (ORFs). Anti-**L1** and -L2 peptide sera recognized **HPV 16** **L1** and L2 fusion proteins in Western blots and by immunopptn. In Western blot anal. of **L1** proteins from different HPV types, antisera to the **L1** peptide reacted only with **HPV 16**, thus identifying an **HPV 16** type-specific linear epitope. Anti-L2 peptide sera reacted with L2 fusion proteins from HPVs 6 and 16, but not from BPV, thus identifying a partially cross-reactive epitope in the **HPV 16** L2. Computer anal. of C terminal amino acid sequences of the **L1** and L2 ORFs of multiple HPV types supported the Western blot findings. Despite the **HPV 16** type specificity found in Western blots, anti-**L1** peptide sera identified nuclear antigen by immunocytochem. in cervical biopsies infected with **HPV 16**, as well as other genital HPV types. Anti-L2 peptide sera failed to recognize antigen in infected tissue.

```
d his

     (FILE 'HOME' ENTERED AT 11:25:48 ON 12 AUG 2004)

     FILE 'MEDLINE' ENTERED AT 11:26:06 ON 12 AUG 2004
L1          2479 S PAPILLOMA VIRUS
L2         14951 S PAPILLOMAVIRUS
L3          3154 S HPV TYPE 16 OR HPV-16
L4          1758 S L1 AND L2
L5             0 S L3 AND DELETED EPITOPE
L6             0 S L3 AND DEVOID EPITOPE
L7            41 S L3 AND MODIFIED
L8            10 S L7 AND "L1"
L9             4 S ITSE
L10            0 S IMMUNODOMINANT TYPE SPECIFC EPITOPE
L11            0 S DEVOID SPECIFIC EPITOPE
L12          302 S L3 AND "L1"
L13            0 S SPECIFC EPITOPE AND L12
L14            1 S SPECIFIC EPITOPE AND L12
L15            0 S EPITOPE DEPELETED
L16            0 S EPITOPE DEPLETED
L17            0 S  DEPLETED EPITOP?
L18            2 S  DELETED EPITOP?
L19            0 S L18 AND L2
L20            0 S D9 ANTIBODY
L21            0 S "D9" ANTIBODY
L22            3 S "V5" ANTIBODY
L23            7 S L12 AND MUTATED

     FILE 'BIOSIS' ENTERED AT 11:44:34 ON 12 AUG 2004
L24            1 S L14

     FILE 'CAPLUS' ENTERED AT 11:44:59 ON 12 AUG 2004
L25            2 S L14

     FILE 'SCISEARCH' ENTERED AT 11:46:21 ON 12 AUG 2004
L26            1 S L14

     FILE 'MEDLINE' ENTERED AT 11:46:53 ON 12 AUG 2004
```

L15: Entry 3 of 4 File: DWPI Mar 26, 2003

DERWENT-ACC-NO: 2001-281675
DERWENT-WEEK: 200327

TITLE: Carrier for delivering substances to cells, useful in antitumor vaccines, comprises the major capsid protein of human papilloma virus modified to be nonimmunogenic

INVENTOR: ANTONSSON, P; DILLNER, J ; KRISTENSSON, K ; LANDO, P ; WALLEN-OHMAN, M ; WALLEN-OEHMAN, M

PRIORITY-DATA: 1999SE-0003534 (September 30, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
ZA 200200886 A	March 26, 2003		022	C07K000/00
WO 200123422 A1	April 5, 2001	E	017	C07K014/025
SE 9903534 A	March 31, 2001		000	C07K014/025
SE 514982 C2	May 28, 2001		000	C07K014/025
AU 200076951 A	April 30, 2001		000	C07K014/025
NO 200200615 A	May 29, 2002		000	C07K000/00
BR 200014666 A	June 18, 2002		000	C07K014/025
EP 1222200 A1	July 17, 2002	E	000	C07K014/025
CZ 200201023 A3	July 17, 2002		000	C07K014/025
SK 200200422 A3	October 8, 2002		000	C07K014/025
KR 2002047195 A	June 21, 2002		000	C07K014/025
HU 200202770 A2	December 28, 2002		000	C07K014/025
CN 1373771 A	October 9, 2002		000	C07K014/025
JP 2003510064 W	March 18, 2003		018	C12N015/09
NZ 516725 A	March 28, 2003		000	C07K014/025

A

INT-CL (IPC): A61 K 39/00; A61 K 39/02; A61 K 39/12; A61 K 48/00; A61 P 1/00; A61 P 11/04; A61 P 15/00; A61 P 15/02; A61 P 31/04; A61 P 31/12; A61 P 33/00; A61 P 35/00; A61 P 35/04; C07 K 0/00; C07 K 14/025; C07 K 19/00; C12 N 15/09; C12 N 15/86

ABSTRACTED-PUB-NO: WO 200123422A
BASIC-ABSTRACT:

NOVELTY - Carrier (A) for introducing a substance (I) into cells comprising the major capsid protein (L1) of human papilloma virus (HPV) that has been engineered to remove major type-specific epitopes that cause production of neutralizing antibodies is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) vaccines containing (A) as active ingredient;

(2) polynucleotides (II) that encode (A); and

(3) vaccines containing (II) as active ingredient;

(4) the prevention or treatment of viral bacterial or parasitic infections by vaccination with (A).

(5) the prevention or treatment of cancer by vaccination with (A).

ACTIVITY - Antitumor; antiviral; antibacterial; antiparasitic.

MECHANISM OF ACTION - Cytotoxic. Induction of a specific cytotoxic T cell response.

USE - (A), or the nucleic acid that encodes them, are used in vaccines for prevention or treatment of

(i) viral, bacterial or parasitic infections, specifically infection by HPV; or

(ii) benign or malignant consequences of HPV infections (specifically warts; laryngeal papillomatosis, and cancer of cervix, penis, vulva, vagina, anus or oropharynx).

ADVANTAGE - (A) does not induce production of neutralizing antibodies against itself, and may induce a response that is cross-reactive to several different HPV serotypes.

ABSTRACTED-PUB-NO: WO 200123422A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

Previous Doc Next Doc Go to Doc#

☐ **41:** Dillner J. Related Articles, Links

Primary screening for human papillomavirus infection.
Best Pract Res Clin Obstet Gynaecol. 2001 Oct;15(5):743-57. Review.
PMID: 11563870 [PubMed - indexed for MEDLINE]

☐ **42:** Konya J, Dillner J. Related Articles, Links

Immunity to oncogenic human papillomaviruses.
Adv Cancer Res. 2001;82:205-38. Review.
PMID: 11447764 [PubMed - indexed for MEDLINE]

☐ **43:** Lehtinen M, Luukkaala T, Wallin KL, Paavonen J, Thoresen S, Dillner J, Hakama M. Related Articles, Links

Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction.
J Clin Virol. 2001 Aug;22(1):117-24.
PMID: 11418359 [PubMed - indexed for MEDLINE]

☐ **44:** Aaltonen LM, Auvinen E, Dillner J, Lehtinen M, Paavonen J, Rihkanen H, Vaheri A. Related Articles, Links

Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis.
J Med Microbiol. 2001 May;50(5):468-71.
PMID: 11339256 [PubMed - indexed for MEDLINE]

☐ **45:** Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J. Related Articles, Links

Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.
N Engl J Med. 2001 Apr 12;344(15):1125-31.
PMID: 11297703 [PubMed - indexed for MEDLINE]

☐ **46:** Lehtinen M, Dillner J, Paavonen J. Related Articles, Links

Vaccinating women against premature death: summary of an International Workshop, Helsinki, Finland, 10.01.2000.
Vaccine. 2001 Jan 8;19(11-12):1347-52. No abstract available.
PMID: 11252250 [PubMed - indexed for MEDLINE]

☐ **47:** Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR. Related Articles, Links

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
J Natl Cancer Inst. 2001 Feb 21;93(4):284-92.

PMID: 11181775 [PubMed - indexed for MEDLINE]

☐ 48: Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angstrom T, Dillner J. Related Articles, Links

Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection.
Br J Cancer. 2000 Apr;82(7):1332-8.
PMID: 10755410 [PubMed - indexed for MEDLINE]

☐ 49: Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, Jellum E, Lehtinen M, Lenner P, Hakulinen T, Narvanen A, Pukkala E, Thoresen S, Youngman L, Paavonen J. Related Articles, Links

Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.
JAMA. 2001 Jan 3;285(1):47-51.
PMID: 11150108 [PubMed - indexed for MEDLINE]

☐ 50: Dillner J, Meijer CJ, von Krogh G, Horenblas S. Related Articles, Links

Epidemiology of human papillomavirus infection.
Scand J Urol Nephrol Suppl. 2000;(205):194-200. Review.
PMID: 11144898 [PubMed - indexed for MEDLINE]

☐ 51: Dillner J, von Krogh G, Horenblas S, Meijer CJ. Related Articles, Links

Etiology of squamous cell carcinoma of the penis.
Scand J Urol Nephrol Suppl. 2000;(205):189-93. Review.
PMID: 11144896 [PubMed - indexed for MEDLINE]

☐ 52: Horenblas S, von Krogh G, Cubilla AL, Dillner J, Meijer CJ, Hedlund PO. Related Articles, Links

Squamous cell carcinoma of the penis: premalignant lesions.
Scand J Urol Nephrol Suppl. 2000;(205):187-8. No abstract available.
PMID: 11144895 [PubMed - indexed for MEDLINE]

☐ 53: Tedeschi R, Kvarnung M, Knekt P, Schulz TF, Szekely L, De Paoli PD, Aromaa A, Teppo L, Dillner J. Related Articles, Links

A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma.
Br J Cancer. 2001 Jan 5;84(1):122-5.
PMID: 11139326 [PubMed - indexed for MEDLINE]

☐ 54: Dillner J. Related Articles, Links

Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection.
J Clin Virol. 2000 Oct;19(1-2):7-23. Review.
PMID: 11091144 [PubMed - indexed for MEDLINE]

☐ 55: Kjellberg L, Wadell G, Bergman F, Isaksson M, Angstrom T, Dillner J. Related Articles, Links

Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser.
Am J Obstet Gynecol. 2000 Nov;183(5):1238-42.
PMID: 11084572 [PubMed - indexed for MEDLINE]

☐ 56: Dillner J. Related Articles, Links

Cervical cancer screening in Sweden.

Eur J Cancer. 2000 Nov;36(17):2255-9.
PMID: 11072216 [PubMed - indexed for MEDLINE]

☐ 57: Ghaderi M, Nikitina L, Peacock CS, Hjelmstrom P, Hallmans G, Wiklund F, Lenner P, Blackwell JM, Dillner J, Sanjeevi CB. Related Articles, Links

Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden.
Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1067-70.
PMID: 11045789 [PubMed - indexed for MEDLINE]

☐ 58: Silins I, Kallings I, Dillner J. Related Articles, Links

Correlates of the spread of human papillomavirus infection.
Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):953-9.
PMID: 11008914 [PubMed - indexed for MEDLINE]

☐ 59: Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. Related Articles, Links

A population-based five-year follow-up study of cervical human papillomavirus infection.
Am J Obstet Gynecol. 2000 Sep;183(3):561-7.
PMID: 10992174 [PubMed - indexed for MEDLINE]

☐ 60: Kibur M, Koskela P, Dillner J, Leinikki P, Saikku P, Lehtinen M, Hakama M. Related Articles, Links

Seropositivity to multiple sexually transmitted infections is not common.
Sex Transm Dis. 2000 Sep;27(8):425-30.
PMID: 10987446 [PubMed - indexed for MEDLINE]

Items 41-60 of 168 Previous Page 3 of 9 Next
Display Summary Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37